7 completed, 2 unknown, 1 recruiting, 1 withdrawn. 11 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 7, Unknown 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Boostrix: new trials by email Literature Review of Boostrix trials Research Report on Boostrix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults GC3111B, Boostrix® - Tetanus-diphtheria-acellular Pertussis (Tdap) | Phase 1 / Phase 2 | Recruiting | GC Biopharma Corp | 120 | 2025-06-05 | 2025-07-10 |
| GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age GBS-NN/NN2 vaccine, Tdap vaccine, Placebo - Streptococcus Agalactiae Infection | Phase 2 / Phase 3 | Withdrawn | Minervax ApS | 2024-12-17 | 2026-10-13 | |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose - Salmonella Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 155 | 2022-09-13 | 2025-11-28 |
| Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children BPZE1 pertussis vaccine and placebo, BPZE1 pertussis vaccine and Boostrix, Placebo and Boostrix - Bordetella Pertussis, Whooping Cough | Phase 2 | Completed | ILiAD Biotechnologies | 368 | 2021-11-11 | 2025-11-06 |
| A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose - Diarrhoea | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 551 | 2021-10-06 | 2026-06-22 |
| A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults GC3111 vaccine, Boostrix® vaccine - Tetanus, Diphtheria | Phase 2 | Unknown | Green Cross Corporation | 213 | 2019-10-14 | 2020-01-23 |
| A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults GVGH S. sonnei (1790GAHB) vaccine 25 μg, GVGH S. sonnei (1790GAHB) vaccine 100 μg, Menveo - Shigella Sonnei Infection | Phase 2 | Completed | GlaxoSmithKline | 74 | 2016-08-08 | 2019-02-18 |
| Maternal Tdap Immunization in Guatemala Tdap, Td - Pertussis, Whooping Cough | Phase 2 | Completed | Emory University | 286 | 2016-07-01 | 2019-10-16 |
| Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine Biological: GC3111 vaccine, Biological: Boostrix® vaccine - Tetanus, Diphtheria | Phase 1 / Phase 2 | Unknown | Green Cross Corporation | 220 | 2016-06-01 | 2016-11-07 |
| Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women RSV vaccine GSK3003891A, Boostrix - Respiratory Syncytial Virus Infections | Phase 2 | Completed | GlaxoSmithKline | 102 | 2016-04-01 | 2018-06-26 |
| Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women RSV vaccine GSK3003895A (formulation 1), RSV vaccine GSK3003898A (formulation 2), RSV vaccine GSK3003899A (formulation 3) - Respiratory Syncytial Virus Infections | Phase 2 | Completed | GlaxoSmithKline | 507 | 2015-03-20 | 2018-07-03 |
Whooping Cough (4) · Diphtheria (2) · Respiratory Syncytial Virus Infections (2) · Tetanus (2) · Diarrhea (1) · Dysentery, Bacillary (1) · Salmonella Infections (1) · Streptococcal Infections (1)
GlaxoSmithKline (5) · Green Cross Corporation (2) · Emory University (1) · GC Biopharma Corp (1) · ILiAD Biotechnologies (1) · Minervax ApS (1)
Belgium (3) · South Korea (3) · Australia (2) · Kenya (2) · Costa Rica (1) · Czechia (1) · Germany (1) · Guatemala (1) · Malawi (1) · United Kingdom (1) · United States (1)
Saad B. Omer, MBBS,MPH,PhD (1)
PMID 29401325, PMID 31951765, PMID 38853614, PMID 42822488
2014 (1), 2015 (1), 2023 (1)